RAGE — Receptor for Advanced Glycation End Products
A 404-aa pattern-recognition receptor (gene: AGER) that binds an unusually wide range of ligands — AGEs, S100/calgranulin family proteins, β-amyloid, HMGB1 (reduced form per Shin 2025), and other DAMPs — and transduces sustained NF-κB and JAK/STAT activation in response. Highly expressed in lung (alveolar epithelium baseline-high — atypical for a pattern-recognition receptor), but upregulated on macrophages, endothelial cells, vascular smooth-muscle cells, microglia, and senescent cells under inflammatory/diabetic/aging conditions. A central convergence node where AGE-driven (glycation), HMGB1-driven (DAMP/SASP), and S100-driven (inflammatory) signals all funnel into the same NF-κB-amplifying loop.
The aging-relevant logic:
- AGE accumulation with age drives RAGE engagement → chronic NF-κB → endothelial dysfunction, vascular stiffening, microvascular complications. See advanced-glycation-end-products and glucosepane.
- Reduced HMGB1 (ReHMGB1) from senescent cells drives RAGE engagement → senescence propagation (per shin-2025-rehmgb1-paracrine-senescence). The recipient cell’s RAGE → JAK2 → STAT1 + PI3K-AKT/NF-κB p65 activation drives SASP gene expression and cell-cycle arrest. Shin 2025 confirmed this by Western blot (ReHMGB1 increased RAGE protein, p-AKT, p-NF-κB p65, p-JAK2, p-STAT1 vs OxHMGB1 or PBS; n = 3, p < 0.05 to < 0.01) and pharmacological rescue (FPS-ZM1 at 100 nM RAGE antagonist abrogated ReHMGB1-induced senescence; the JAK2 inhibitor Momelotinib at 0.3 μM also rescued).
- Receptor feed-forward. RAGE is itself an NF-κB transcriptional target — engagement upregulates the receptor, amplifying responsiveness to ligand. This positive-feedback architecture distinguishes RAGE from most pattern-recognition receptors.
The result is that RAGE sits at a privileged position in inflammaging biology: a single receptor that integrates glycation damage, sterile DAMP release, and SASP propagation.
Splice variants
- Full-length membrane RAGE (mRAGE / flRAGE) — canonical signaling form; 3 extracellular Ig-like domains (V, C1, C2), single transmembrane span, short cytoplasmic tail with diaphanous-1 binding site for downstream signaling.
- Soluble RAGE (sRAGE) — circulating decoy isoform lacking the transmembrane + cytoplasmic domain. Produced by alternative splicing (esRAGE / RAGE_v1) and by ADAM10/MMP9-mediated proteolytic cleavage of mRAGE. Circulating sRAGE acts as a ligand sink — higher sRAGE is generally protective against RAGE-driven pathology. sRAGE plasma levels are reduced in type 2 diabetes, cardiovascular disease, and Alzheimer’s; some longevity cohorts show preserved sRAGE in centenarians. needs-replication
This dual-isoform architecture creates a natural therapeutic handle: rebalancing the mRAGE/sRAGE ratio toward sRAGE attenuates pathology. Recombinant sRAGE has been tested preclinically.
Ligands
| Ligand class | Examples | Aging relevance |
|---|---|---|
| AGEs | CML-modified proteins, methylglyoxal-derived AGEs, glucosepane crosslinks | Diabetic complications; vascular aging; ECM stiffening |
| S100 / calgranulins | S100A8, S100A9 (calprotectin), S100B, S100A12 | Inflammaging; myeloid-driven sterile inflammation |
| HMGB1 (reduced) | hmgb1 redox-state-selective per Shin 2025 | Senescence propagation; SASP amplification |
| β-amyloid | Aβ40, Aβ42 | Alzheimer’s neurodegeneration |
| LPA / lysophosphatidic acid | LPA species | Lipid-driven RAGE activation; context-dependent |
| Lysophosphatidylcholine, oxidized phospholipids | oxLDL components | Atherogenesis |
The ligand promiscuity is structural — the V domain binds many different beta-sheet-rich or amyloid-like motifs.
Downstream signaling
RAGE has no intrinsic kinase activity. Engagement of the cytoplasmic tail recruits:
- Diaphanous-1 (DIAPH1) — primary direct binding partner; required for downstream cytoskeletal + signaling responses.
- TIRAP/MyD88 — couples to NF-κB activation.
- PKC isoforms, Rac1, Cdc42 — cytoskeletal + ROS-generating arms.
- JAK2/STAT3 — direct coupling reported in some contexts; canonical in the Shin 2025 ReHMGB1 → JAK/STAT senescence axis.
Net output: persistent NF-κB activation + ROS generation + JAK/STAT activation, with cytoskeletal remodeling.
Druggability
druggability-tier: 2 — high-quality probes exist; one failed Phase 3 (Alzheimer’s); no aging-indication trial:
- Azeliragon (TTP488) — small-molecule RAGE antagonist; Phase 3 STEADFAST trial in mild Alzheimer’s disease failed for primary efficacy endpoint (2018). Now in subgroup-targeted Phase 3 (diabetic AD patients). Probes the receptor but the Alzheimer’s failure tempers enthusiasm for the AGE-RAGE-amyloid mechanism.
- FPS-ZM1 — research-grade RAGE antagonist (rodent BBB-penetrant); widely used in mechanism studies.
- Soluble RAGE (sRAGE) decoy — recombinant; preclinical.
- Anti-RAGE monoclonal antibodies — preclinical (e.g., XT-M4).
- DIAPH1 disruption — emerging strategy from the Schmidt lab; targets the cytoplasmic-tail / DIAPH1 interface; preclinical only.
Aging-context tier reflects the lack of an aging-validated clinical drug despite multiple advanced-stage probes. Shin 2025 nominates RAGE blockade as a senomorphic strategy — repurposing of existing RAGE probes for an aging indication has not been attempted. needs-human-replication.
Extrapolation
| Dimension | Status |
|---|---|
| Pathway conserved in humans? | yes (RAGE, ligands, downstream all conserved) |
| Phenotype conserved in humans? | partial (azeliragon Phase 3 failure in AD; diabetic complications association well-established) |
| Replicated in humans? | partial (AGE-RAGE-vascular axis: yes via epidemiology; ReHMGB1-RAGE-senescence axis: no human data yet) |
Cross-references
hmgb1 · shin-2025-rehmgb1-paracrine-senescence · advanced-glycation-end-products · glucosepane · carboxymethyl-lysine · nf-kb · jak-stat-pathway · chronic-inflammation · cellular-senescence · altered-intercellular-communication · sasp